Gong Ben-Fa, Wang Ying, Lin Dong, Wei Hui, Li Wei, Zhou Chun-Lin, Liu Bing-Cheng, Liu Kai-Qi, Zhang Guang-Ji, Liu Yun-Tao, Li Yan, Wei Shu-Ning, Gong Xiao-Yuan, Zhao Xing-Li, Qiu Shao-Wei, Gu Run-Xia, Mi Ying-Chang, Wang Jian-Xiang
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Dec;24(6):1615-1621. doi: 10.7534/j.issn.1009-2137.2016.06.001.
To evaluate the influence of FLT3-ITD mutation on long term survival of newly diagnosed patients with acute promyelocytic leukemia (APL).
Long term survival of 170 newly diagnosed APL patients was retrospective analyzed. Mutation rate of FLT3-ITD was assayed, and its influence on disease-free survival(DFS) or overall survival (OS) was analyzed.
The mutation rate of FLT3-ITD in newly diagnosed patients with APL was 14.1%. WBC count at diagnosis was higer in FLT3-ITD positive group than that in negative group, and the mutation rate of FLT3-ITD was highest in high risk group. Induction death rate in FLT3-ITD positive and negative group were 12.5% and 2.9%, respectively (P=0.031). Complete remission(CR) rate in 2 groups were 83.3% and 97.1%(P=0.004). The 5-year OS rates in 2 groups were 87.5±6.8% and 90.6±2.6% (P=0.740). The 5-year DFS in 2 groups were 82.8±9.1% and 83.6±3.4%(P=0.928).
FLT3-ITD mutation is related with high peripheral white blood cell count in APL, the APL with FLT3-ITD mutation has higher induction death rate and lower CR rate than those in that without FLT3-ITD mutation, but FLT3-ITD mutation did not affect on long term DFS and OS.
评估FLT3-ITD突变对新诊断急性早幼粒细胞白血病（APL）患者长期生存的影响。
回顾性分析170例新诊断APL患者的长期生存情况。检测FLT3-ITD突变率，并分析其对无病生存（DFS）或总生存（OS）的影响。
新诊断APL患者中FLT3-ITD突变率为14.1%。FLT3-ITD阳性组诊断时白细胞计数高于阴性组，且FLT3-ITD突变率在高危组最高。FLT3-ITD阳性组和阴性组诱导死亡率分别为12.5%和2.9%（P=0.031）。两组完全缓解（CR）率分别为83.3%和97.1%（P=0.004）。两组5年总生存率分别为87.5±6.8%和90.6±2.6%（P=0.740）。两组5年无病生存率分别为82.8±9.1%和83.6±3.4%（P=0.928）。
FLT3-ITD突变与APL患者外周血白细胞计数高有关，FLT3-ITD突变的APL诱导死亡率高于无FLT3-ITD突变者，CR率低于无FLT3-ITD突变者，但FLT3-ITD突变不影响长期DFS和OS。
